BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Qin B, Huang G, Yang Q, Zhao M, Chen H, Gao W, Yang M. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. BMJ Open 2019;9:e033161. [PMID: 31784448 DOI: 10.1136/bmjopen-2019-033161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
3 Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord 2021;283:472-9. [PMID: 33516560 DOI: 10.1016/j.jad.2020.11.106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hutka P, Krivosova M, Muchova Z, Tonhajzerova I, Hamrakova A, Mlyncekova Z, Mokry J, Ondrejka I. Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment. Int J Mol Sci 2021;22:1333. [PMID: 33572767 DOI: 10.3390/ijms22031333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Yang YK, Chen CS, Tsai CF, Chang CM, Lai TJ, Lee CT, Lin CC, Lan TH, Herr KJ. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin 2021;:1-11. [PMID: 34515596 DOI: 10.1080/03007995.2021.1980869] [Reference Citation Analysis]
6 Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Journal of Affective Disorders 2019;250:114-22. [DOI: 10.1016/j.jad.2019.03.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
7 Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
10 Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol 2019;85:240-4. [PMID: 30328132 DOI: 10.1111/bcp.13772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]